2′-C-methyl nucleoside derivatives

Details 2′-C-methyl nucleoside derivatives 2′-C-methyl nucleoside derivatives

2006-10-30

2010-02-23

McIntosh, III, Traviss C (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S045000

Reexamination Certificate

active

07666855

ABSTRACT:
Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

REFERENCES:
patent: 3018302 (1962-01-01), Arnold et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6752981 (2004-06-01), Erion et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 6864244 (2005-03-01), Connolly et al.
patent: 6914054 (2005-07-01), Sommadossi et al.
patent: 7105493 (2006-09-01), Sommadossi et al.
patent: 2003/0225277 (2003-12-01), Kopcho et al.
patent: 2003/0229225 (2003-12-01), Reddy et al.
patent: 2003/0236216 (2003-12-01), Devos et al.
patent: 2004/0006007 (2004-01-01), Gosselin et al.
patent: 2004/0063658 (2004-04-01), Roberts et al.
patent: 2004/0092476 (2004-05-01), Boyer et al.
patent: 2004/0147464 (2004-07-01), Roberts et al.
patent: 2004/0192651 (2004-09-01), Reddy et al.
patent: 2005/0090463 (2005-04-01), Roberts et al.
patent: 2005/0107312 (2005-05-01), Keicher et al.
patent: 2005/0182252 (2005-08-01), Reddy et al.
patent: 2007/0060498 (2007-03-01), Gosselin et al.
patent: 2337262 (1999-11-01), None
patent: WO 97/26883 (1997-07-01), None
patent: WO 97/41211 (1997-11-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 98/22458 (1998-05-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 98/29430 (1998-07-01), None
patent: WO 98/30223 (1998-07-01), None
patent: WO 98/38888 (1998-09-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/00399 (1999-01-01), None
patent: WO 99/04908 (1999-02-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/36074 (1999-07-01), None
patent: WO 99/43691 (1999-09-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/60855 (1999-12-01), None
patent: WO 99/64442 (1999-12-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/24693 (2000-05-01), None
patent: WO 00/25780 (2000-05-01), None
patent: WO 00/44388 (2000-08-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/00622 (2001-01-01), None
patent: WO 01/27114 (2001-04-01), None
patent: WO 01/45509 (2001-06-01), None
patent: WO 01/45642 (2001-06-01), None
patent: WO 01/46212 (2001-06-01), None
patent: WO 01/47883 (2001-07-01), None
patent: WO 01/60379 (2001-08-01), None
patent: WO 01/60381 (2001-08-01), None
patent: WO 01/68034 (2001-09-01), None
patent: WO 01/68663 (2001-09-01), None
patent: WO 01/77091 (2001-10-01), None
patent: WO 01/79246 (2001-10-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/04425 (2002-01-01), None
patent: WO 02/06246 (2002-01-01), None
patent: WO 02/15904 (2002-02-01), None
patent: WO 02/16382 (2002-02-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/20497 (2002-03-01), None
patent: WO 02/32920 (2002-04-01), None
patent: WO 02/48116 (2002-06-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 02/051425 (2002-07-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 02/102307 (2002-12-01), None
patent: WO03/062255 (2003-01-01), None
patent: WO 03/014821 (2003-02-01), None
patent: WO 03/014822 (2003-02-01), None
patent: WO 03/026589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/034690 (2003-04-01), None
patent: WO 03/034709 (2003-04-01), None
patent: WO 03/037908 (2003-05-01), None
patent: WO 03/051881 (2003-06-01), None
patent: WO 03/051896 (2003-06-01), None
patent: WO 03/051897 (2003-06-01), None
patent: WO 03/051898 (2003-06-01), None
patent: WO 03/051899 (2003-06-01), None
patent: WO 03/052053 (2003-06-01), None
patent: WO 03/057287 (2003-07-01), None
patent: WO 03/062255 (2003-07-01), None
patent: WO 03/062256 (2003-07-01), None
patent: WO 03/093290 (2003-11-01), None
patent: WO 2004/002422 (2004-01-01), None
patent: WO 2004/002999 (2004-01-01), None
patent: WO 2004/003000 (2004-01-01), None
patent: WO 2004/013300 (2004-02-01), None
patent: WO 2004/028481 (2004-04-01), None
patent: WO2004/041834 (2004-05-01), None
patent: WO 2004/046331 (2004-06-01), None
patent: WO 2005/016927 (2005-02-01), None
patent: WO 2005/037214 (2005-04-01), None
Stella, “Prodrugs as Therapeutics”, Expert Opinion Ther. Patents (2004) 14(3), pp. 277-280.
Allison, A. C. and Eugui, E. M., “Immunosuppressive and other anti-rheumatic activities of mycophenolate mofetil,”Variability in Response to Anti-Rheumatic Drugs1993, 165-188.
Aleksiuk, O. et al., “Proximal intraannular modifications of calix[4]arene via its spirodienone derivative,”J. Chem. Soc., Chem. Comm. 1993, 11-13.
Anderson, R. C. and Shapiro, M. J., “2-Chloro-4(R),5(R)-dimethyl-2-oxo-1,3,2-dioxphospholane, a new chiral derivatizing agent,”J. Org. Chem. 1984, 49, 1304-1305.
Aso, M. et al., “Synthesis of a new class of spin-labeled purine ribonucleosides and development of novel nucleophilic reaction to form 2,6,8-trifunctionalized purine derivatives,”J. Chem. Soc., Perkin Trans. 2000, 2, 1637-1638.
Beigelman, L. N. et al., “New synthesis of 2′-C-Methylnucleotides starting fromD-glucose andD-ribose,”Carbohydrate Research1987, 166,219-232.
Bentrude, W. G. et al., “Stereo- and regiochemistries of the oxidations of 2-methoxy-5-tert-butyl-1,3,2-dioxaphosphorinanes and the cyclic methyl 3′,5′-phosphite of thymidine by H2O/I2and O2/AIBN to p-chiral phosphates.17O NMR assignment of phosphorus configuration to the diastereomeric thymidine cyclic methyl 3′,5′-monophosphates,”J. Am. Chem. Soc. 1989, 111, 3981-3987.
Bertocchio, R. And Dreux, J.,Mémoires Présentés a la Société Chimique1962, 307, 1809-1813.
Corey, E. J. and Reichard, G. A., “Enantioselective and practical synthesis ofR- andS-fluoxetines,”Tet. Lett. 1989, 30(39), 5207-5210.
Cullis, P. M., “The stereochemical course of iodine-water oxidation of dinucleoside phosphite triesters,”J. Chem. Soc., Chem. Comm. 1984, 1510-1512.
Curran, D. P. and Fenk, C. J., “Thermolysis of bis[2-[(trimethylsilyl)oxy]prop-2-yl]furoxan(TOP-furoxan). The first practical method for intermolecular cycloaddition of an in situ generated nitrile oxide with 1,2-di- and trisubstituted olefins,”J. Am. Chem. Soc. 1985, 107, 6023-6028.
Dornow, A. et al.,Chem. Ber. 1949, 3, 254-257.
Dymock, B. W., “Emerging therapies for hepatitis C virus infection,”Emerging Drugs2001, 6(1), 13-42.
Freer, R. et al., “A new route to famciclovir via palladium catalysed allylation,”Tetrahedron2000, 56, 4589-4595.
Hanson, R. L., “Regioslective enzymatic aminoacylation of lobucavir to give an intermediate for lobucavir prodrug,”Biorganic&Medicinal Chemistry2000, 8, 2681-2687.
Harry-O'kuru, R. E. et al., “A short, flexible route toward 2′-C-branched ribonucleosides,”J. Org. Chem. 1997, 62, 1754-1759.
Hoeffler, J. F. et al., “Chemical synthesis of enantiopure 2-C-methyl-D-erythritol 4-phosphate, the key intermediate in the mevalonate-independent pathway for isoprenoid biosynthesis,”Tetrahedron2000, 56, 1485-1489.
Iwata, C. et al., “Asymmetric functionalization at a prochiral carbon center by the aid of sulfinyl chirality: a selective formation of 6-substituted (3R,SS)- and (3R,SS)-3-hydroxymethyl-3, 4-dihydro-5-(p-tolyl)sulfinyl-2H-pyrans,”Tet. Lett. 1987, 28(27), 3131-3134.
Kimura, J. et al., “Studies on Nucleosides and Nucleotides,”Bulletin of the Chemical Society of Japan1979, 52(4), 1191-1196.
Kirschbaum, J., “Amantadine,”Anal Profiles Drug Subs. 1983, 12; 1-36.
Mikolajczyk, M. and Luczak, J., “Dimethyl selenoxide oxidation of trivalent phosphorus compounds, thio-and selenophosphoryl compounds, and thiocarbonyl compounds. Stereochemical studies and selective modification of the thiocarbonyl-containing nucleic acid components,”J. Org. Chem. 1978, 43(11), 2132-

Affiliated with

Also associated with

Rating

2′-C-methyl nucleoside derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2′-C-methyl nucleoside derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2′-C-methyl nucleoside derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4163998